Mark E. Bunnage sells VRTX common stock

Mark E. Bunnage reported sales of common stock under Rule 144.

Rhea-AI Filing Summary

Mark E. Bunnage reported sales of common stock under Rule 144. The filing lists four dispositions: 12/29/2025 — 23 shares for $10,649.00; 02/11/2026 — 2,021 shares for $930,529.03; 02/17/2026 — 2,437 shares for $1,192,814.02; and 02/18/2026 — 1,182 shares for $559,889.76. The transactions are reported as sales by the holder and include a separate 620-share restricted stock vesting on 02/24/2026 noted as compensation.

Insights

Corporate Governance Analyst

Insider sales of common stock were reported across four trades in late 2025 and February 2026.

The filing documents specific dispositions by Mark E. Bunnage with per-trade counts and dollar amounts, consistent with Rule 144 reporting for restricted or control-person sales. These are ordinary filings that disclose transaction details.

Impact appears routine; subsequent filings may clarify whether sales were pre-arranged or routine portfolio actions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transactions did Mark E. Bunnage report in the Rule 144 filing for VRTX?

He reported four sales and one vesting event. The filing lists sales on 12/29/2025, 02/11/2026, 02/17/2026, and 02/18/2026, plus a 620-share restricted stock vesting on 02/24/2026 labeled as compensation.

How many shares and proceeds are shown for each reported sale?

Each sale is listed with quantity and dollar proceeds. The filing shows 23 shares for $10,649.00; 2,021 for $930,529.03; 2,437 for $1,192,814.02; 1,182 for $559,889.76.

Does the filing indicate whether the sales were open-market or part of a plan for VRTX?

The excerpt lists transaction types but not execution method. It reports dispositions with dates and amounts; the filing text does not specify whether trades were open-market, pursuant to a 10b5-1 plan, or otherwise.

Is there any indication of proceeds received by the issuer in this filing?

No issuer proceeds are reported in these transactions. The entries show sales by the holder and a restricted stock vesting described as compensation; the filing does not state that the issuer received sale proceeds.

What is the significance of the 620-share entry dated 02/24/2026?

That entry records restricted stock vesting as compensation. The filing shows a 620-share Common stock item on 02/24/2026 identified as "Restricted Stock Vesting" and categorized as compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 11:02 AM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002100735
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERTEX PHARMACEUTICALS INC / MA
SEC File Number	000-19319
Address of Issuer	50 NORTHERN AVENUE BOSTON MASSACHUSETTS 02210
Phone	6173416393
Name of Person for Whose Account the Securities are To Be Sold	Bunnage Mark E.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	620	301537.00	254034190	02/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/24/2026	Restricted Stock Vesting	Issuer			620	02/24/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark E. Bunnage 50 Northern Avenue Boston MA 02210	Common	12/29/2025	23	10649.00
Mark E. Bunnage 50 Northern Avenue Boston MA 02210	Common	02/11/2026	2021	930529.03
Mark E. Bunnage 50 Northern Avenue Boston MA 02210	Common	02/17/2026	2437	1192814.02
Mark E. Bunnage 50 Northern Avenue Boston MA 02210	Common	02/18/2026	1182	559889.76

144: Remarks and Signature

Remarks
Date of Notice	02/25/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Audrey McMillen, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Mark E. Bunnage
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)